European Patent Office

T 0886/91 (Hepatitis B virus/ BIOGEN INC.) vom 16.06.1994

Europäischer Rechtsprechungsidentifikator
ECLI:EP:BA:1994:T088691.19940616
Datum der Entscheidung
16. Juni 1994
Aktenzeichen
T 0886/91
Antrag auf Überprüfung von
-
Anmeldenummer
79303017.2
IPC-Klasse
C12N 15/00
Verfahrenssprache
Englisch
Verteilung
An die Kammervorsitzenden und -mitglieder verteilt (B)
Amtsblattfassungen
Keine AB-Links gefunden
Weitere Entscheidungen für diese Akte
-
Zusammenfassungen für diese Entscheidung
-
Bezeichnung der Anmeldung
Recombinant DNA, hosts transformed with it and polypeptides produced by the hosts; processes for their preparation; detection processes using the polypeptides; compositions and means containing the polypeptides; DNA sequences.
Name des Antragstellers
BIOGEN, INC.
Name des Einsprechenden
(01) Abbott Laboratories
(02) Takeda Chemical Industries, Ltd
(03) Warcoin, Jacques Cabinet REGIMBEAU
(04) SmithKline Beecham Corporation
(05) Institut Pasteur Etablissement public
Medeva PLC (Intervener)
Kammer
3.3.02
Leitsatz
-
Schlagwörter
Admissibility of intervention of assumed infringer during appeal (yes)
Entitlement to priority
Sufficiency of disclosure (yes)
Industrial applicability (yes)
Citability of document published between the second and third priority dates against subject-matter entitled to the third priority or filing date (yes)
Novelty (yes)
Inventive step-main request (no)
Inventive step-first auxiliary request (yes)
Orientierungssatz
-

ORDER

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the first instance with the order to maintain the patent on the basis of the claims of the first auxiliary request (non-AT and AT), as submitted in the oral proceedings, and a description to be adapted thereto.